IP Verse

Improved Cell Compositions And Methods For Cancer Therapy - EP3091999

The patent EP3091999 was granted to Hadasit Medical Research Services on May 7, 2025. The application was originally filed on Jan 8, 2015 under application number EP15734922A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3091999

HADASIT MEDICAL RESEARCH SERVICES
Application Number
EP15734922A
Filing Date
Jan 8, 2015
Status
Patent Maintained As Amended
Apr 4, 2025
Grant Date
May 7, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SCRIPTJul 19, 2022SCRIPTADMISSIBLE
SCRIPTJul 19, 2022SCRIPT INTELLECTUALADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2009017014
OPPOSITIONUS2009017014
OPPOSITIONUS2011171204

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous , "Homo sapiens SLAM family member 6 (SLAMF6), transcript variant 3, mRNA", Nucleotide, (20190319), Database accession no. NM_001184715, URL: NCBI, XP055948900-
OPPOSITION- Anonymous , "Homo sapiens SLAM family member 6 (SLAMF6), transcript variant 4, mRNA", Nucleotide, (20190319), Database accession no. NM_001184716, URL: NCBI, XP055948948-
OPPOSITION- Anonymous , "RecName: Full=SLAM family member 6;", UniProt, (20040524), Database accession no. Q96DU3, URL: NCBI, XP055948892-
OPPOSITION- crawford et al., "Chemotherapy-Induced Neutropenia - Risks, Consequences, and New Directions for Its Management", CANCER CYTOPATHOLOGY, Wiley InterScience, US, US , (20040115), vol. 100, no. 2, ISSN 1097-0142, pages 228 - 236, XP008141453-
OPPOSITION- Galit Eisenberg, Rutenberg Abraham, Frankenburg Shoshana, Engelstein Roni, Merims Sharon, Machlenkin Arthur, Pato Aviad, Ben-David Inna, Kuznetz Anna, Gelfand Yael, Lotem Michal, Peretz Tamar, "DISCOVERY OF THE IMMUNE MODULATORY ROLE OF SLAMF6 THROUGH TUMOR-CD8 T CELL INTERACTIONS", (20140101), pages 1 - 1, (20170321), XP055356850-
OPPOSITION- Robin Kageyama; JenniferL. Cannons; Fang Zhao; Isharat Yusuf; Christopher Lao; Michela Locci; PamelaL. Schwartzberg; Shane Crotty;, "The Receptor Ly108 Functions as a SAP Adaptor-Dependent On-Off Switch for T Cell Help to B Cells and NKT Cell Development", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20120508), vol. 36, no. 6, doi:10.1016/j.immuni.2012.05.016, ISSN 1074-7613, pages 986 - 1002, XP028502127
OPPOSITION- P. A. Valdez, Et Al, "NTB-A, a New Activating Receptor in T Cells That Regulates Autoimmune Disease", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20040430), vol. 279, no. 18, doi:10.1074/jbc.M312313200, ISSN 0021-9258, pages 18662 - 18669, XP055256984
OPPOSITION- BOTTINO CRISTINA ET AL, "NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease.", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20010806), vol. 194, no. 3, doi:10.1084/jem.194.3.235, ISSN 0022-1007, pages 235 - 246, XP002187972
OPPOSITION- Richard Wu, Marie-Andrée Forget, Jessica Chacon, Chantale Bernatchez, Cara Haymaker, Jie Qing Chen, Patrick Hwu, Laszlo G. Radvanyi, "Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma : Current Status and Future Outlook", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, US , (20120101), vol. 18, no. 2, doi:10.1097/PPO.0b013e31824d4465, ISSN 1528-9117, pages 160 - 175, XP055568011
OPPOSITION- Hajaj Emma, Zisman Elad, Tzaban Shay, Merims Sharon, Cohen Jonathan, Klein Shiri, Frankenburg Shoshana, Sade-Feldman Moshe, Tabach Yuval, Yizhak Keren, Navon Ami, Stepensky Polina, Hacohen Nir, Peretz Tamar, Veillette André, Karni Rotem, Eisenberg Galit, Lotem Michal, "Alternative splicing of SLAMF6 in human T cells creates a co-stimulatory isoform that counteracts the inhibitory effect of the full-length receptor", bioRxiv, doi:10.1101/2020.08.21.262238, (20200821), pages 1 - 33, bioRxiv, URL: https://www.biorxiv.org/content/10.1101/2020.08.21.262238v1.full.pdf, (20220804), XP055948887
OPPOSITION- Wouter Korver, Et Aj, "The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (20070501), vol. 137, no. 4, doi:10.1111/j.1365-2141.2007.06569.x, ISSN 0007-1048, pages 307 - 318, XP055256983
OPPOSITION- Galit Eisenberg, Roni Engelstein, Anat Geiger-Maor, Emma Hajaj, Sharon Merims, Shoshana Frankenburg, Ronny Uzana, Abraham Rutenberg, Arthur Machlenkin, Gabi Frei, Tamar Peretz, Michal Lotem, "Soluble SLAMF6 Receptor Induces Strong CD8 + T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo", CANCER IMMUNOLOGY RESEARCH, American Association for Cancer Research, US, US , (20180201), vol. 6, no. 2, doi:10.1158/2326-6066.CIR-17-0383, ISSN 2326-6066, pages 127 - 138, XP055497033
OPPOSITION- Yigit Burcu, Wang Ninghai, Ten Hacken Elisa, Chen Shih-Shih, Bhan Atul K., Suarez-Fueyo Abel, Katsuyama Eri, Tsokos George C., Chiorazzi Nicholas, Wu Catherine J., Burger Jan A., Herzog Roland W., Engel Pablo, Terhorst Cox, "SLAMF6 as a Regulator of Exhausted CD8 + T Cells in Cancer", CANCER IMMUNOLOGY RESEARCH, American Association for Cancer Research, US, US , (20190901), vol. 7, no. 9, doi:10.1158/2326-6066.CIR-18-0664, ISSN 2326-6066, pages 1485 - 1496, XP055795478
OPPOSITION- ELFLEIN K, et al, "Rapid recovery from T lymphopenia by CD28 superagonist therapy.", Blood, American Society of Hematology, US, US , (20030901), vol. 102, no. 5, doi:10.1182/blood-2002-11-3586, ISSN 0006-4971, pages 1764 - 1770, XP002346689
OPPOSITION- R. Uzana, Eisenberg G., Sagi Y., Frankenburg S., Merims S., Amariglio N., Yefenof E., Peretz T., Machlenkin A., Lotem M., "Trogocytosis Is a Gateway to Characterize Functional Diversity in Melanoma-Specific CD8+ T Cell Clones", The Journal of Immunology, Williams & Wilkins Co., US, US , (20120101), vol. 188, no. 2, doi:10.4049/jimmunol.1101429, ISSN 0022-1767, pages 632 - 640, XP055356805
OPPOSITION- Hajaj Emma, Eisenberg Galit, Klein Shiri, Frankenburg Shoshana, Merims Sharon, Ben David Inna, Eisenhaure Thomas, Henrickson Sarah E, Villani Alexandra Chloé, Hacohen Nir, Abudi Nathalie, Abramovich Rinat, Cohen Jonathan E, Peretz Tamar, Veillette Andre, Lotem Michal, "SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint", eLife, (20200303), vol. 9, doi:10.7554/eLife.52539, pages e52539-1 - e52539-23, XP055779686
OTHER- Crawford et al, "Chemotherapy-Induced Neutropenia - Risks, Consequences, and New Directions for Its Management", Cancer, vol. 100, no. 2, (20040115), pages 228 - 237, XP008141453-
OTHER- Eisenberg et al, "Soluble SLAMF6 Receptor Induces Strong CD8 + T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo", CANCER IMMUNOLOGY RESEARCH, vol. 6, no. 2, (20180000), pages 127 - 138, XP055497033
SEARCH- WU R ET AL, "Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, (20120301), vol. 18, no. 2, doi:10.1097/PPO.0B013E31824D4465, ISSN 1528-9117, pages 160 - 175, XP009170931 [X] 12 * abstract; figure 1 * * page 167 - page 168 * [A] 1-2,13-14
SEARCH- ELFLEIN K ET AL, "Rapid recovery from T lymphopenia by CD28 superagonist therapy", BLOOD, THE AMERICAN SOCIETY OF HEMATOLOGY, & 53RD ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); SAN DIEGO, CA, USA; DECEMBER 10 -13, 2011, (20030901), vol. 102, no. 5, doi:10.1182/BLOOD-2002-11-3586, ISSN 0006-4971, pages 1764 - 1770, XP002346689 [A] 5-8 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents